{"id":"iron-sucrose-injection-usp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Iron sucrose is a polynuclear iron(III) hydroxide sucrose complex that provides bioavailable iron for erythropoiesis. The sucrose coating protects iron from premature release and oxidation, allowing efficient uptake by iron-binding proteins and incorporation into hemoglobin and myoglobin. This formulation is particularly useful in patients who cannot tolerate or absorb oral iron, such as those with chronic kidney disease on hemodialysis.","oneSentence":"Iron sucrose delivers iron directly into the bloodstream as a stable complex to replenish iron stores and support hemoglobin synthesis in patients with iron deficiency.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:52.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia in patients with chronic kidney disease on hemodialysis"},{"name":"Iron deficiency anemia in patients with chronic kidney disease not on dialysis"},{"name":"Iron deficiency anemia in patients receiving erythropoiesis-stimulating agents"}]},"trialDetails":[{"nctId":"NCT03933813","phase":"PHASE1, PHASE2","title":"Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-07-29","conditions":"Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia","enrollment":9},{"nctId":"NCT00236938","phase":"PHASE3","title":"Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2002-07","conditions":"Anemia","enrollment":121},{"nctId":"NCT04155814","phase":"PHASE1","title":"Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2019-09-19","conditions":"Bioequivalance","enrollment":196},{"nctId":"NCT00236951","phase":"PHASE3","title":"Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2003-02","conditions":"Anemia","enrollment":224},{"nctId":"NCT00719459","phase":"PHASE1","title":"Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2008-06","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT00534144","phase":"PHASE1","title":"Comparison Between Effects of Two Iron Preparations on Protein in the Urine","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2007-09","conditions":"Kidney Failure, Chronic, Anemia, Iron-Deficiency","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"iron sucrose injection USP","genericName":"iron sucrose injection USP","companyName":"American Regent, Inc.","companyId":"american-regent-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iron sucrose delivers iron directly into the bloodstream as a stable complex to replenish iron stores and support hemoglobin synthesis in patients with iron deficiency. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients receiving erythropoiesis-stimulating agents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}